Ribosomal protein L23a pseudogene 58 (RPL23AP58)

Ribosomal protein L23a pseudogene 58 (RPL23AP58) is classified as a processed pseudogene in the human genome[3][6]. Pseudogenes are DNA sequences similar to known genes but are typically non-functional; they do not code for active proteins, usually due to mutations that prevent their transcription or translation. RPL23AP58 is one of many pseudogenes related to ribosomal protein L23a, which is a genuine protein-coding gene forming part of the 60S ribosomal subunit[5]. However, there is no evidence indicating that RPL23AP58 itself encodes a functional protein or that it plays a direct biological, pathological, or therapeutic role[3][6]. No data support its current value as a drug target, biomarker, or contributor to known disease mechanisms. The gene is annotated as a pseudogene in key genomic resources[3][6]. Notes on target correctness: - The term refers to a pseudogene, not a protein-coding gene, receptor, enzyme, transporter, or other established therapeutic target or biomarker. - There is no evidence that RPL23AP58 fulfils any canonical function, nor that it is actionable in drug discovery, clinical diagnostics, or disease biology[3][6]. - Several sources describe related pseudogenes (such as RPL23AP53) being studied for potential correlations with expression or disease, but no such data exist for RPL23AP58 specifically[7]. - No drug, mechanism of action, or safety issue is described for RPL23AP58. Summary: RPL23AP58 is a non-functional processed pseudogene related to ribosomal protein L23a and does not represent a valid molecular target in therapeutic research or clinical medicine[3][6].

None known